恆林股份(603661.SH)及子公司擬向銀行申請綜合授信額度不超6億元
格隆匯 12 月 4日丨恆林股份(603661.SH)公佈,公司於2020年12月4日召開第五屆董事會第二十二次會議,會議審議通過了《關於公司及子公司擬向銀行申請綜合授信額度的議案》。
根據公司財務狀況及經營需要,公司及所屬子公司擬申請銀行綜合授信總額不超過人民幣6億元,授信期限以簽署的授信協議為準,授信期限內授信額度可循環使用。授信有效期限為公司董事會通過之日至2020年年度股東大會通過之前。上述擬申請授信額度尚需各家銀行最終審批,且擬申請授信額度不等於公司的實際融資金額,實際融資金額將視公司運營資金的實際需求確定,在授信額度內以各家銀行與公司實際發生的融資金額為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.